News | Joshua Ofman, M.D., MSHS, joins Board of Directors

July 9, 2019

LOS ANGELES–(BUSINESS WIRE)–Cell BT, Inc. (CBI), an immuno-therapy company focused on the discovery and development of innovative cancer therapeutics based on next generation CAR-T antibody constructs directed to novel biological targets, today announced that Joshua J. Ofman, M.D., MSHS, has been appointed to the CBI Board of Directors.

Read More